December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
Genmab cans its antibody-drug conjugate against Axl kinase, an approach on which Bergenbio has gone all in.
With one portfolio asset rejected by the FDA and another looking dicey, Sumitomo looks pretty reliant on Vibegron.
A crucial second pivotal trial in uterine fibroids fails to dispel concerns about the company’s linzagolix.
Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.
An analysis of the sellside’s consensus forecast changes reveals the winners and losers of 2019.